Literature DB >> 33747910

The Prognostic Value of Radiomics Features Extracted From Computed Tomography in Patients With Localized Clear Cell Renal Cell Carcinoma After Nephrectomy.

Xin Tang1,2, Tong Pang1, Wei-Feng Yan1, Wen-Lei Qian1, You-Ling Gong2, Zhi-Gang Yang1.   

Abstract

BACKGROUND AND
PURPOSE: Radiomics is an emerging field of quantitative imaging. The prognostic value of radiomics analysis in patients with localized clear cell renal cell carcinoma (ccRCC) after nephrectomy remains unknown.
METHODS: Computed tomography images of 167 eligible cases were obtained from the Cancer Imaging Archive database. Radiomics features were extracted from the region of interest contoured manually for each patient. Hierarchical clustering was performed to divide patients into distinct groups. Prognostic assessments were performed by Kaplan-Meier curves, COX regression, and least absolute shrinkage and selection operator COX regression. Besides, transcriptome mRNA data were also included in the prognostic analyses. Endpoints were overall survival (OS) and disease-free survival (DFS). Concordance index (C-index), decision curve analysis and calibration curves with 1,000 bootstrapping replications were used for model's validation.
RESULTS: Hierarchical clustering groups from nephrographic features and mRNA can divide patients into different prognostic groups while clustering groups from corticomedullary or unenhanced phase couldn't distinguish patients' prognosis. In multivariate analyses, 11 OS-predicting and eight DFS-predicting features were identified in nephrographic phase. Similarly, seven OS-predictors and seven DFS-predictors were confirmed in mRNA data. In contrast, limited prognostic features were found in corticomedullary (two OS-predictor and two DFS-predictors) and unenhanced phase (one OS-predictors and two DFS-predictors). Prognostic models combining both nephrographic features and mRNA showed improved C-index than any model alone (C-index: 0.927 and 0.879 for OS- and DFS-predicting, respectively). In addition, decision curves and calibration curves also revealed the great performance of the novel models.
CONCLUSION: We firstly investigated the prognostic significance of preoperative radiomics signatures in ccRCC patients. Radiomics features obtained from nephrographic phase had stronger predictive ability than features from corticomedullary or unenhanced phase. Multi-omics models combining radiomics and transcriptome data could further increase the predictive accuracy.
Copyright © 2021 Tang, Pang, Yan, Qian, Gong and Yang.

Entities:  

Keywords:  clear cell renal cell carcinoma; computed tomography; predictive model; prognosis; radiomics

Year:  2021        PMID: 33747910      PMCID: PMC7973240          DOI: 10.3389/fonc.2021.591502

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  28 in total

1.  Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy.

Authors: 
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2016-08

2.  Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker.

Authors:  Vicky Goh; Balaji Ganeshan; Paul Nathan; Jaspal K Juttla; Anup Vinayan; Kenneth A Miles
Journal:  Radiology       Date:  2011-08-03       Impact factor: 11.105

Review 3.  The Past, Present and Future of Immunotherapy for Metastatic Renal Cell Carcinoma.

Authors:  Alexander J Chang; Lei Zhao; Ziwen Zhu; Kyle Boulanger; Huaping Xiao; Mark R Wakefield; Qian Bai; Yujiang Fang
Journal:  Anticancer Res       Date:  2019-06       Impact factor: 2.480

4.  Harmonization of multi-site diffusion tensor imaging data.

Authors:  Jean-Philippe Fortin; Drew Parker; Birkan Tunç; Takanori Watanabe; Mark A Elliott; Kosha Ruparel; David R Roalf; Theodore D Satterthwaite; Ruben C Gur; Raquel E Gur; Robert T Schultz; Ragini Verma; Russell T Shinohara
Journal:  Neuroimage       Date:  2017-08-18       Impact factor: 6.556

5.  The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository.

Authors:  Kenneth Clark; Bruce Vendt; Kirk Smith; John Freymann; Justin Kirby; Paul Koppel; Stephen Moore; Stanley Phillips; David Maffitt; Michael Pringle; Lawrence Tarbox; Fred Prior
Journal:  J Digit Imaging       Date:  2013-12       Impact factor: 4.056

6.  Intrinsic dependencies of CT radiomic features on voxel size and number of gray levels.

Authors:  Muhammad Shafiq-Ul-Hassan; Geoffrey G Zhang; Kujtim Latifi; Ghanim Ullah; Dylan C Hunt; Yoganand Balagurunathan; Mahmoud Abrahem Abdalah; Matthew B Schabath; Dmitry G Goldgof; Dennis Mackin; Laurence Edward Court; Robert James Gillies; Eduardo Gerardo Moros
Journal:  Med Phys       Date:  2017-03       Impact factor: 4.071

7.  Textural differences in apparent diffusion coefficient between low- and high-stage clear cell renal cell carcinoma.

Authors:  Andrea S Kierans; Henry Rusinek; Andrew Lee; Mohammed B Shaikh; Michael Triolo; William C Huang; Hersh Chandarana
Journal:  AJR Am J Roentgenol       Date:  2014-12       Impact factor: 3.959

8.  CT Textural Analysis of Large Primary Renal Cell Carcinomas: Pretreatment Tumor Heterogeneity Correlates With Histologic Findings and Clinical Outcomes.

Authors:  Meghan G Lubner; Nicholas Stabo; E Jason Abel; Alejandro Munoz Del Rio; Perry J Pickhardt
Journal:  AJR Am J Roentgenol       Date:  2016-05-04       Impact factor: 3.959

9.  Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis.

Authors:  Shih-Ying Huang; Benjamin L Franc; Roy J Harnish; Gengbo Liu; Debasis Mitra; Timothy P Copeland; Vignesh A Arasu; John Kornak; Ella F Jones; Spencer C Behr; Nola M Hylton; Elissa R Price; Laura Esserman; Youngho Seo
Journal:  NPJ Breast Cancer       Date:  2018-08-16

10.  A Deep Learning-Based Radiomics Model for Differentiating Benign and Malignant Renal Tumors.

Authors:  Leilei Zhou; Zuoheng Zhang; Yu-Chen Chen; Zhen-Yu Zhao; Xin-Dao Yin; Hong-Bing Jiang
Journal:  Transl Oncol       Date:  2018-12-17       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.